EPCAM and lymphoma: Thus, bispecific antibodies based on CD3-TCR have become a hot spot in the research of tumor targeting therapy recently, especially anti-CD3/CD20 therapy for lymphoma and anti-CD3/EpCAM for GC (26–28).